Contact This Organization

Proteios Technology, Inc.

Proteios is developing 1) recombinant protein purification kits and will soon be extending the technology for the purification of biopharmaceuticals during manufacturing, 2) a multivariate cell separation technology for cell enrichment during cell therapy research and a cGMP-compliant instrument for cell therapy manufacturing of autologous CAR-T cell therapies and allogeneic NK cell therapies, and 3) a POC device for the detection of the SARS-Cov-2 virus.
Mission/Vision
Proteios' vision is to apply our technology to help lower the cost of healthcare, including: diagnostics, small-molecule drugs, biopharmaceuticals, cell therapies, and gene therapies.
Type of Organization
Startup - Newly established businesses, investable
Size of Organization
0-10
Organization Mailing Address

580 Wilderness Peak Drive NW
Issaquah, WA 98027
United States

cGMP instrument for multivariate cell separation during cell therapy manufacturing
Cell therapies have emerged as highly promising treatments for cancers and diseases resulting from viral infection. We are designing a cGMP instrument for multivariate cell separation during cell therapy manufacturing, with an initial focus on T cells for autologous CAR-T cell therapies and Natural Killer cells for allogeneic viral and cancer therapies. Our technology avoids the use of antibodies and magnetics beads, and allows for cell separations based on multiple factors in a single step.
Category of Innovation
Life Sciences - Life science solutions are those solutions that are delivered as a drug or device that typically require federal approval
Intended End User
Provider - Individuals or organizations responsible for providing care to patients (e.g. doctors, nurses, hospital/clinic administrators, etc.)
Researcher/Academic
Impactful Innovation Stage (Click Here for Details)
Solution
Problem (i.e. barrier, issue, complication, etc.) being solved for the end user
Current immunomagnetic cell isolation technologies are expensive, lack many GMP-grade reagents, employ antibody reagents with a short shelf life - resulting in inflexibility during planning, can take up to 10 hours to complete cell separation, and can only isolate cells based on selection of one cell surface antigen factor at a time. The latter results in back-to-back cell separations to be performed to isolate on two factors (e.g., CD4 & CD8 or CD3 & CD56) with an accompany 2x increase in cost and 2x increase in time.
Idea/solution to the problem, if applicable
Proteios' multivariate cell separation technology allows for the simultaneous selection of target cells based on multiple factors, resulting in a 75% reduction in cell separation time and 50% reduction in cost of reagents. The Proteios Chimera reagent is composed of a small synthetic polypeptide and synthetic DNA aptamer, and exhibits a long shelf life and is easily produced under GMP conditions.
Level of adoption (i.e. list of customers/users, testimonials, etc.), if applicable
Proteios Technology has received letters of support from:

Jeanette Boudreau, Ph.D., Dalhousie University, Canada
Christian Chabannon, M.D., Ph.D., Centre d'Investigations Cliniques en Biothérapies, France
Keith Jerome, M.D., Ph.D., University of Washington & Fred Hutchinson Cancer Research Center
Antonio Moreira, Ph.D., University of Maryland
Monica Thakar, M.D., Fred Hutchinson Cancer Research Center & Seattle Children's Hospital
Brian Till, M.D., Fred Hutchinson Cancer Research Center
Funding Stage
Grant funded
List of Funding Sources (if applicable)
National Institutes of Health (NIH)
National Science Foundation (NSF)
University of Washington CoMotion
Larta Institute
Certifications?
No